Hexima Limited announced the appointment of Phillip Rose as Chief Commercial Officer, based in the U.S. Phillip Rose reports to Michael Aldridge, Managing Director & CEO. Mr. Rose has over 30 years of leadership experience in the pharmaceutical industry, including President and CEO of the dermatology focused Obagi Medical Products, Vice President and General Manager of North America for Valeant (now Bausch Healthcare Companies) as well as Vice President Hospital Sales at Glaxo Inc. (now GSK).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.013 AUD | 0.00% | 0.00% | -27.78% |
Mar. 22 | Hexima Secures R&D Tax Rebate for Fiscal Year 2023 | MT |
Mar. 19 | Hexima Changes Address | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.78% | 1.41M | |
+4.09% | 43.84B | |
+46.34% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- HXL Stock
- News Hexima Limited
- Phillip Rose Appoints Phillip Rose as Chief Commercial Officer